A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).

Trial Details

NCT ID

NCT04951635

Phase

PHASE3

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Almonertinib
Placebo Almonertinib

Locations (sample)

Ji'nan, Shandong, China

Key Eligibility Criteria

Provision of informed consent before any study-specific procedures, sampling and analyses.
Male or female, age at least 18 years.
Histologically or cytologically confirmed diagnosis of primary non-small lung cancer (NSCLC) on predominantly non-squamous pathology who present wi…
The tumor harbours one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19Del, L858R), either alone or in combi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →